XNAS · SVRA
+2.61% · +$0.1400 · Vol 1.3M
Market closed · last close 4:00 PM ET · price as of 17:45:47 ET
Savara Inc.

Savara Inc.

PHARMACEUTICAL PREPARATIONS
$5.51
Card
Relationship Map

Follow $SVRA

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $SVRA by email

Veridion Score

BETALOW CONF · 4 of 6 factors measuredMethodology
Valuation absence reason unknown · Sentiment absence reason unknown
SVRA
Savara Inc.
Mon Sep 21 · market closed · Markets closed · resumes Tue 9:30 ET
Middle range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

47/ 100
Veridion Score
Middle range · LOW confidence · 4 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 4 of 6 factors measured · Mon Sep 21 · market closed · Markets closed · resumes Tue 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is SVRA moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading SVRA catalysts
About Savara Inc.
PHARMACEUTICAL PREPARATIONS
Listed since
1996
Employees
70
Country
US

Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$5.44
Day high
$5.51
Day low
$5.36
Previous close
$5.37
52W high
$6.94
-20.61% from high
52W low
$3.37
60% of range
Market cap
$1.1B
EPS
$-0.5700
Beta
0.94
Shares out
205.5M
Volume
1.3M
0.89× rel vol
Avg volume
1.5M
VWAP
$5.44
Price history computed in-house
1W
+4.75%
1M
-1.43%
3M
-5.49%
1Y
+57.88%
YTD
-8.62%
SMA 50 $5.49 · above
SMA 200 $5.59 · below
52W position 60%

SVRA overview

Veridion Score
47
Registered · 2026-09-21
4 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around SVRA.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading SVRA Form 4 filings
Public disclosures

Congress activity in SVRA

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for SVRA in the cached public ledger.

Federal contracts

SVRA contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for SVRA in this window.
Lobbying spend

SVRA lobbying filings, year to date.

Registered lobbying filings matched to Savara Inc..

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for SVRA in this window.
Loading news for SVRA
Analyst ratings
Sovereign unlock shows live analyst consensus for SVRA.
Options
Sovereign unlock shows live options positioning for SVRA.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.